A Phase 1 Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies
This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
An Open-Label, Multi-Center Phase I Study to Investigate the Safety and Tolerability of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20 Directed Antibody Therapy
- ClinicalTrials.gov Identifier: NCT02290951
- Protocol Number: 15-212
- Principal Investigator: Jon Arnason
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required